

Correction to announcement number 0140E made at 07:00 on 08/04/2025 (Steriwave in first Swiss hospital): The RNS included the incorrect title for Professor Dr. Dr. Harald Essig. All other information was correct.

## **ONDINE BIOMEDICAL INC.**

("Ondine Biomedical", "Ondine", or the "Company")

### **Switzerland's University Hospital Zurich undertakes independent research study on Steriwave for preoperative nasal decolonization**

Ondine Biomedical Inc. (LON: OBI) reports that University Hospital Zurich (USZ) has initiated an independent clinical study evaluating Steriwave<sup>®</sup>. This marks the first Swiss deployment of Ondine's nasal decolonization technology to combat surgical site infections (SSI).

The study, titled "*Preoperative Microbial Reduction of the Nasal Cavity with Antimicrobial Photodynamic Therapy (aPDT)*," is led by Professor Dr. Dr. Harald Essig, Head of the Department of Cranio-Maxillo-Facial and Oral Surgery at USZ. This research will assess the efficacy of Steriwave in rapidly reducing preoperative nasal microbial burden - a key factor in SSI rates and hospital length of stay.

*"Reducing post-surgical infections remains a top priority in Cranio-Maxillo-Facial and Oral Surgery, particularly in high-risk procedures," said Prof. Essig. "This study allows us to evaluate a novel, fast-acting approach to nasal decolonization that could represent a meaningful advancement in infection prevention."*

Steriwave antimicrobial photodynamic therapy is a light-activated antimicrobial with ultra-fast efficacy that destroys a broad spectrum of pathogens, including antibiotic-resistant strains. This innovative technology is used to sanitize the nasal cavity, a primary reservoir for bacteria, viruses, and fungi that can lead to SSIs and hospital-acquired infections (HAI), particularly in high-risk surgical procedures. Unlike traditional approaches that rely on repeat doses of topical antibiotics and take days to take effect, Steriwave works immediately with a single, five-minute treatment, making it an ideal solution for preoperative nasal decolonization.

The USZ study builds on extensive clinical use in Canada and the UK which have established that Steriwave enhances patient safety as well as combatting antimicrobial resistance.

#### **Carolyn Cross, CEO of Ondine Biomedical, stated:**

*"Ondine Biomedical is proud to collaborate with the distinguished research team at University Hospital Zurich, where there is a strong and well-established history of researching aPDT. We appreciate their initiation of this study, and are confident the findings will further validate Steriwave's ability to rapidly and safely reduce pathogens associated with HAI. Deploying Steriwave at USZ is another important step in our mission to provide innovative, broad-spectrum solutions for infection prevention and to address the growing global threat of antimicrobial resistance."*

**Enquiries:**  
**Ondine Biomedical Inc.**  
Carolyn Cross, CEO

[www.ondinebio.com](http://www.ondinebio.com)  
Via Vane Percy & Roberts

#### **Strand Hanson Limited (Nominated & Financial Adviser)**

James Harris, Richard Johnson

+44 (0)20 7409 3494

#### **RBC Capital Markets (Broker)**

Rupert Walford, Kathryn Deegan

+44 (0)20 7653 4000

#### **Vane Percy & Roberts (Media Contact)**

Simon Vane Percy, Amanda Bernard

+44 (0)77 1000 5910

#### **About University Hospital Zurich (USZ):**

University Hospital Zurich is a leading medical center in Switzerland, renowned for its comprehensive healthcare services and cutting-edge research, including in the field of photodynamic therapy. The Department of Cranio-Maxillo-Facial and Oral Surgery at USZ specializes in the diagnosis, surgical treatment, and rehabilitation of complex conditions involving the facial skeleton, jaws, and oral cavity. Its clinical focus lies in restoring both function and aesthetics through advanced reconstructive techniques, trauma care, and oncologic surgery. In parallel, the clinic engages in cutting-edge research on

inflammatory diseases and osteomyelitis of the craniofacial bones, with a particular emphasis on innovative treatment approaches that operate independently of conventional antibiotic strategies such as Photodynamic Inactivation. Further research priorities include the development and clinical application of bioactive ceramics for bone regeneration, the use of computer-assisted surgical procedures with patient-specific implants, and novel strategies for the early detection and treatment of oral and maxillofacial cancers.

#### **About Ondine Biomedical Inc.**

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies (also known as 'photodisinfection'). Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada, Australia, Mexico and several other countries under the name Steriwave<sup>®</sup>. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

#### **About Steriwave<sup>®</sup> Nasal Photodisinfection**

Steriwave is an innovative antimicrobial treatment that rapidly eliminates a broad spectrum of pathogens, including bacteria, viruses, and fungi. Using a proprietary, light-activated antimicrobial agent, Steriwave works in a simple two-step process: the agent is first applied to the nostrils with a nasal swab, then activated by a specific wavelength of red light. This activation triggers an oxidative burst that destroys pathogens within a single five-minute treatment-providing offering a robust alternative to traditional antibiotics without the risk of developing resistance.

Nasal decolonization is recommended in the 2016 WHO Global guidelines for the prevention of surgical site infections,[1] and the Society for Healthcare Epidemiology of America (SHEA) guidelines, published in May 2023, recommend nasal decolonization for major surgical procedures.[2]

---

[1] Surgical Site Infection Prevention: Key facts on decolonization of nasal carriers of Staphylococcus aureus. World Health Organization. [\(link\)](#)

[2] Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2023;44(5):695-720. [\(link\)](#)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRASSIFIAEISELL